Dr. Reddy's Laboratories announces the launch of Redyx in India

Report : Anustup Kundu

News Desk, News Nation 360: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, announced the launch of Remdesivir, under a brand name Redyx in India. The launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr. Reddy’s the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India. Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms. M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories, told they will continue their efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms their commitment to bringing in critical medicine for patients suffering from Covid-19 in India. Dr. Reddy’s Redyx is available in the strength of 100 mg vial. 

  • Facebook
  • Twitter
  • Instagram